Interventions for preventing the progression of autosomal dominant polycystic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Bolignano, Davide ^a   Palmer, Suetonia C ^b   Ruospo, Marinella ^c,d   Zoccali, Carmine ^a   Craig, Jonathan C ^e,f   Strippoli, Giovanni F M ^c,f,g,h  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Diaverum   (Sweden)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e UNIVERSITY OF SYDNEY   (Australia)

^f University of Sydney   (Australia)

^g UNIVERSITY OF BARI   (Italy)

^h Diaverum Academy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOPEPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOSARTAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METOPROLOL; OCTREOTIDE; PLACEBO; PRAVASTATIN; RAMIPRIL; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; TELMISARTAN; TOLVAPTAN; UNINDEXED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; TARGET OF RAPAMYCIN KINASE;

ABDOMINAL CRAMP; ALBUMINURIA; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; DATA ANALYSIS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIZZINESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HEADACHE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERNATREMIA; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY FUNCTION; KIDNEY PAIN; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; KIDNEY STRUCTURE; LOW DRUG DOSE; META ANALYSIS; MORTALITY; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SUDDEN DEATH; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THIRST; TREATMENT OUTCOME; XEROSTOMIA; ADULT; ANTAGONISTS AND INHIBITORS; CHILD; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; CHILD; DISEASE PROGRESSION; EICOSAPENTAENOIC ACID; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOR SERINE-THREONINE KINASES;

EID: 84950993432     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010294.pub2     Document Type: Review

References (132)

1. Apperloo AJ, Rensma PL. Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine 1996;335(8):596-7. [MEDLINE: 8684417]
2. Curren CG. Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine 1996;335(8):596-7. [MEDLINE: 8684418]
3. Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002;20(1):37-47. [MEDLINE: 11817991]
4. Locatelli F, Carbarns IR, Maschio G, Mann JF, Ponticelli C, Ritz E, et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International -Supplement 1997;63:S63-6. [MEDLINE: 9407424]
5. Locatelli F, Del Vecchio L, Andrulli S, Marai P, Tentori F. The role of underlying nephropathy in the progression of renal disease. Kidney International -Supplement 2000;75:S49-55. [MEDLINE: 10828762]
6. Mann JF, Maschio G, Alberti D, AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract]. Nephrology 1997;3(Suppl 1):S39. [CENTRAL: CN-00461248]
7. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, et al. The use of benazepril in the treatment of progressive renal disease [abstract]. 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65.
8. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese F, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine 1996;334(15):939-45. [MEDLINE: 8596594]
9. Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology 1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]
10. Maschio, G. Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine 1996;335(8):596-7.
11. van Hout BA, Simeon GP, McDonnell J, Mann JF. Economic evaluation of benazepril in chronic renal insufficiency. Kidney International -Supplement 1997;52(Suppl 63):S159-62. [MEDLINE: 9407447]
12. Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013;382(9903):1485-95. [MEDLINE: 23972263]
13. Biao S. Clinical observation on adult polycystic kidney disease treated with calcitriol and 'qijudihuang mixt' [abstract no: P1057]. Nephrology 1997;3(Suppl 1):S338. [CENTRAL: CN-00460393]
14. Cadnapaphornchai MA, Fick-Brosnahan GM, Duley I, Johnson AM, Strain JD, DeGroff CG, et al. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). Contemporary Clinical Trials 2005;26(2):211-22. [MEDLINE: 15837441]
15. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Prospective change in renal volume and function in children with ADPKD. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(4):820-9. [MEDLINE: 19346430]
16. Cadnapaphornchai MA, Fick-Brosnahan GM, Duley I, Johnson AM, Strain JD, DeGroff CG, et al. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). Contemporary Clinical Trials 2005;26(2):211-22. [MEDLINE: 15837441]
17. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Prospective change in renal volume and function in children with ADPKD. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(4):820-9. [MEDLINE: 19346430]
18. Cadnapaphornchai MA, Fick-Brosnahan GM, Duley I, Johnson AM, Strain JD, DeGroff CG, et al. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). Contemporary Clinical Trials 2005;26(2):211-22. [MEDLINE: 15837441]
19. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Prospective change in renal volume and function in children with ADPKD. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(4):820-9. [MEDLINE: 19346430]
20. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases 2000;35(3):427-32. [MEDLINE: 10692268]
21. Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 1999;14(5):1113-6. [MEDLINE: 10344347]
22. Ecder T, McFann KK, Johnson AM, Chapman CB, Edelstein CL, Tison M, et al. Reversal of left ventricular hypertrophy in autosomal dominant polycystic kidney disease (ADPKD) patients with rigorous blood pressure (BP) control [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):534A. [CENTRAL: CN-00550560]
23. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. Journal of the American Society of Nephrology 2002;13(7):1733-9. [MEDLINE: 12089368]
24. Chrispijn M, Drenth JP. Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials [Electronic Resource] 2011;12:246. [MEDLINE: 22104015]
25. Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial in polycystic liver disease patients [abstract]. Journal of Hepatology 2013;58(Suppl 2):S557-8. [EMBASE: 71055656]
26. Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Journal of Hepatology 2013;59(1):153-9. [MEDLINE: 23499726]
27. Fassett RG, Coombes JS, Packham D, Fairley KF, Kincaid-Smith P. Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology & Nephrology 2010;44(1):56-61. [MEDLINE: 20034362]
28. Kincaid-Smith P, Vincent J, Fairley K. Randomised controlled trial of HMG CO A reductase inhibitor in polycystic renal disease in man [abstract no: A1733]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):375A. [CENTRAL: CN-00446097]
29. Higashihara E, Nutahara K, Horie S, Muto S, Hosoya T, Hanaoka K, et al. The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD. Nephrology Dialysis Transplantation 2008;23(9):2847-52. [MEDLINE: 18372389]
30. Hogan M, Masyuk TV, Torres V, King BF, Kim BF, LaRusso NF. OctreotideLAR inhibits hepatorenal cystogenesis in the human polycystic liver diseases. Hepatology 2009;50(Suppl 4):328A. [EMBASE: 70073470]
31. Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrology Dialysis Transplantation 2012;27(9):3532-9. [MEDLINE: 22773240]
32. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. Journal of the American Society of Nephrology 2010;21(6):1052-61. [MEDLINE: 20431041]
33. Chrispijn M, Keimpema L, Nevens F, Vanslembrouck R, Oijen MG, Hoffmann AD, et al. Growth of liver volume stops after one year of lanreotide in patients with polycystic livers. Journal of Hepatology 2010;52(Suppl 1):S31. [EMBASE: 70130918]
34. Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Alimentary Pharmacology & Therapeutics 2012;35(2):266-74. [MEDLINE: 22111942]
35. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, et al. Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial [abstract]. Hepatology 2009;50(Suppl 4):328A.
36. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009;137(5):1661-8. [MEDLINE: 19646443]
37. Melemadathil S, Kamal M. Efficacy and safety of sirolimus in reducing cyst volume in patients with autosomal dominant polycystic kidney disease [abstract]. Nephrology Dialysis Transplantation 2013;28:i81-2. [EMBASE: 71075211]
38. Mora FP, Codianni P, Liern M, Grammatico D, Vallejo G. Use of rapamycin to reduce the pathologic kidney volume growth in autosomal polycystic kidney disease [abstract]. Pediatric Nephrology 2013;28(8):1492. [EMBASE: 71127367]
39. Nakamura T, Ushiyama C, Takahashi Y, Tanaka A, Shimada N, Ebihara I, et al. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron 2001;88(1):80-2. [MEDLINE: 11340355]
40. Nakamura T, Ushiyama C, Takahashi Y, Tanaka A, Shimada N, Ebihara I, et al. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron 2001;88(1):80-2. [MEDLINE: 11340355]
41. Nakamura T, Ushiyama C, Takahashi Y, Tanaka A, Shimada N, Ebihara I, et al. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron 2001;88(1):80-2. [MEDLINE: 11340355]
42. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, et al. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. American Journal of the Medical Sciences 2012;343(1):46-51. [MEDLINE: 21760473]
43. Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron 2005;99(1):c18-23. [MEDLINE: 15637459]
44. Stallone G, Infante B, Bruno F, Bristogiannis C, Grandaliano G, Macarini L, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (ADPKD) study: a randomized, controlled study [abstract]. Nephrology Dialysis Transplantation 2012;27(Suppl 2):ii46-7. [EMBASE: 70765435]
45. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrology Dialysis Transplantation 2012;27(9):3560-7. [MEDLINE: 22785114]
46. Stallone G, Infante B, Bruno F, Bristogiannis C, Grandaliano G, Macarini L, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (ADPKD) study: a randomized, controlled study [abstract]. Nephrology Dialysis Transplantation 2012;27(Suppl 2):ii46-7. [EMBASE: 70765435]
47. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrology Dialysis Transplantation 2012;27(9):3560-7. [MEDLINE: 22785114]
48. Stallone G, Infante B, Bruno F, Bristogiannis C, Grandaliano G, Macarini L, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (ADPKD) study: a randomized, controlled study [abstract]. Nephrology Dialysis Transplantation 2012;27(Suppl 2):ii46-7. [EMBASE: 70765435]
49. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrology Dialysis Transplantation 2012;27(9):3560-7. [MEDLINE: 22785114]
50. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clinical Journal of the American Society of Nephrology: CJASN 2010;5(5):783-9. [MEDLINE: 20185596]
51. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney International 2005;68(1):206-16. [MEDLINE: 15954910]
52. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, et al. Sirolimus therapy to halt the progression of ADPKD. Journal of the American Society of Nephrology 2010;21(6):1031-40. [MEDLINE: 20466742]
53. Soliman A, Zamil S, Lotfy A, Ismail E. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment. Transplantation Proceedings 2012;44(10):2936-9. [MEDLINE: 23195001]
54. Soliman AR, Ismail E. Sirolimus therapy for patients with adult polycystic kidney disease -a pilot study [abstract no: TH-PO053]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):123A. [CENTRAL: CN-00716073]
55. Soliman AR, Ismail E, Zamil S, Lotfy A. Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study. Transplantation Proceedings 2009;41(9):3639-41. [MEDLINE: 19917358]
56. Braun M, Young J, Reiner CS, Poster D, Krauer F, Kistler AD, et al. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD Trial. PLoS ONE [Electronic Resource] 2012;7(10):e45868. [MEDLINE: 23071528]
57. Braun M, Young J, Reiner CS, Poster D, Wuthrich RP, Serra AL. Ovarian toxicity from sirolimus. New England Journal of Medicine 2012;366(11):1062-4. [MEDLINE: 22417271]
58. Serra A, Poster D, Kistler AD, Krauer F, Raina F, Voneckardstein A, et al. Safety, tolerability and adherence of sirolimus in autosomal dominant polycystic kidney disease [abstract no: 2.5]. Swiss Medical Weekly 2008;138(Suppl 167):4S.
59. Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, et al. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2009;24(11):3334-42. [MEDLINE: 19525519]
60. Serra AL, Kistler AD, Poster D, Struker M, Wuthrich RP, Weishaupt D, et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrology 2007;8:13. [MEDLINE: 17868472]
61. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. New England Journal of Medicine 2010;363(9):820-9. [MEDLINE: 20581391]
62. Serra AL, Poster D, Kistler AD, Wuthrich RP. Interim analysis of efficacy, safety and tolerability of sirolimus in patients with autosomal dominant polycystic kidney disease (ADPKD) [abstract no: SA064]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
63. Temmerman F, Vanslembrouck R, Coudyzer W, Bammens B, Laleman W, Cassiman D, et al. The reduction in liver volume in polycystic liver disease with lanreotide is dose dependent and is most pronounced in patients with the highest liver volume [abstract]. Journal of Hepatology 2012;56:S547. [EMBASE: 70749518]
64. Chapman AB, Torres VE, Grantham JJ, Shoaf SS, Ouyang JJ, Czerwiec FS. A phase IIB pilot study of the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA), in patients with ADPKD [abstract no: F-FC139]. Journal of the American Society of Nephrology 2005;16:68A. [CENTRAL: CN-00653783]
65. Grantham JJ, Chapman AB, Torres VE, Ouyang JJ, Shoaf SE, Czerwiec FS. Acute and chronic osmostasis after vasopressin V2 receptor inhibition with tolvaptan in ADPKD [abstract no: F-PO106]. Journal of the American Society of Nephrology 2005;16(October):361A. [CENTRAL: CN-00653784]
66. Torres VE, Wang X, Ward CJ, Grantham JJ, Chapman AB, Ouyang JJ, et al. Urine aquaporin 2 and cyclic AMP responses to tolvaptan administration in autosomal dominant polycystic kidney disease [abstract no: F-PO108]. Journal of the American Society of Nephrology 2005;16(October):361A. [CENTRAL: CN-00653785]
67. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(10):2499-507. [MEDLINE: 21903984]
68. Torres VE, Grantham JJ, Chapman AB, Watnick T, Kedzierski K, Ouyang JJ, et al. Phase 2 open-label study to determine safety, tolerability and efficacy of split-dose tolvaptan in ADPKD [abstract no: SA-PO077]. Journal of the American Society of Nephrology 2007;18:361A-2A. [CENTRAL: CN-00653786]
69. Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, et al. Urine osmolality and outcome in ADPKD: Results from the TEMPO 3:4 trial [abstract]. Nephrology Dialysis Transplantation 2014;29(Suppl 3):iii6. [EMBASE: 71491481]
70. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine 2012;367(25):2407-18. [MEDLINE: 23121377]
71. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Higashihara E, Perrone RD, et al. Tolvaptan-treatment of ADPKD confers persistent EGFR improvement: Results from the TEMPO 4:4 extension trial [abstract]. Nephrology Dialysis Transplantation 2014;29(Suppl 3):iii6. [EMBASE: 71491483]
72. Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. American Journal of Kidney Diseases 2011;57(5):692-9. [MEDLINE: 21333426]
73. Ulusoy S, Ozkan G, Orem C, Kaynar K, Kosucu P, Kiris A. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Renal Failure 2010;32(8):913-7. [MEDLINE: 20722556]
74. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2001;16(11):2152-7. [MEDLINE: 11682660]
75. van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2003;18(11):2314-20. [MEDLINE: 14551359]
76. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine 2010;363(9):830-40. [MEDLINE: 20581392]
77. Watson ML, Macnicol AM, Borg-Costanzi J, Vareesanghip K, Chauveau D, Cohen G, et al. A long-term comparison of the effects of renal function of BP control with either atenolol (A) or enalapril (E) in polycystic kidney disease (PKD) [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):428A.
78. Mueller H, Schmieder RE, Zeltner R, Poliak R, Graf S, Schulze BD. Determinants for the treatment of hypertensive patients with autosomal dominant polycystic kidney disease (ADPKD): choice of drug versus blood pressure (BP) control [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):109A. [CENTRAL: CN-00653777]
79. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2008;23(2):573-9. [MEDLINE: 17984104]
80. Doulton TW, Saggar-Malik AK, He FJ, Carney C, Markandu ND, Sagnella GA, et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. Journal of Hypertension 2006;24(5):939-45. [MEDLINE: 16612257]
81. Kanno Y, Suzuki H, Okada H, Takenaka T, Saruta T. Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. Qjm 1996;89(1):65-70. [MEDLINE: 8730344]
82. Suzuki H, Kanno Y, Okada H, Konishi K, Nakazato Y, Okamiya Y, et al. Renal protective effects of calcium channel blocker on hypertensive patients with autosomal dominant polycystic kidney disease [abstract]. Journal of the American Society of Nephrology 1994;5(3):568.
83. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. American Journal of the Medical Sciences 2005;330(4):161-5. [MEDLINE: 16234607]
84. Sharma RK, Kohli R, Rathore D, Gupta A, Gupta RK. Magnetic resonance based studies as a marker of disease progression in autosomal-dominant polycystic kidney disease and the effect of simvastatin on disease progression [abstract]. Indian Journal of Nephrology 2004;14:126.
85. Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clinical Journal of the American Society of Nephrology: CJASN 2014;9(5):881-8. [MEDLINE: 24721888]
86. NCT01233869. A phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety, clinical activity and pharmacokinetics of bosutinib (PF-05208763) versus placebo in subjects with autosomal dominant polycystic kidney disease (ADPKD). www.clinicaltrials.gov/ct2/show/NCT01233869 2014. [MEDLINE: 9407447]
87. Riegersperger M, Herkner H, Sunder-Plassmann G. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial. Trials 2015;16(1):182. [MEDLINE: 25899445]
88. Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW. Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemporary Clinical Trials 2011;32(3):437-45. [MEDLINE: 21266204]
89. Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN 2014;9(5):889-96. [MEDLINE: 24721893]
90. Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, et al. Rationale and design of the DIPAK 1 Study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases 2014;63(3):446-55. [MEDLINE: 24342522]
91. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(4):1197-204. [MEDLINE: 18579674]
92. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Philip MJ, et al. The HALT polycystic kidney disease trials: design and implementation. Clinical Journal of The American Society of Nephrology: CJASN 2010;5(1):102-9. [MEDLINE: 20089507]
93. Miskulin D, Chapman A, Steinman T, Schrier R, Torres V, Perrone R, et al. Impact of autosomal dominant polycystic kidney disease on quality of life: results from the HALT-PKD study [abstract no: TH-PO052]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):123A. [CENTRAL: CN-00756923]
94. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. American Journal of Kidney Diseases 2014;63(2):214-26. [MEDLINE: 24183837]
95. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, et al. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(10):2508-15. [MEDLINE: 21903983]
96. Rahbari-Oskoui FF, Miskulin DC, Hogan MC, Fielder O, Torres VE, Bost JE, et al. Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease. Blood Pressure Monitoring 2011;16(2):47-54. [MEDLINE: 21415814]
97. Schrier R, Torres V, Chapman A, Perrone R, Miller JP, Meyers C, et al. Design of the HALT-PKD studies [abstract no: F-PO105]. Journal of the American Society of Nephrology 2005;16:361A. [CENTRAL: CN-00792560]
98. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. New England Journal of Medicine 2014;371(24):2255-66. [MEDLINE: 25399733]
99. Steinman TI, Schrier RW, Torres VE, Chapman AB, Perrone RD, Grantham JJ, et al. The HALT-PKD trials: selection of novel endpoints and study update [abstract no: PUB023]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):837A. [CENTRAL: CN-00691816]
100. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. New England Journal of Medicine 2014;371(24):2267-76. [MEDLINE: 25399731]
101. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney International 2012;81(6):577-85. [MEDLINE: 22205355]
102. Torres VE, Schrier RW, Chapman AB, Perrone RD, Miskulin D, Steinman T, et al. Achievement and maintenance of blood pressure targets in HALT-PKD [abstract no: TH-PO051]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):123A. [CENTRAL: CN-00755104]
103. O'Shaugnessy K. A rotation study through the main therapeutic classes of antihypertensive in patients with polycystic kidney disease and hypertension. controlled-trials.com/ISRCTN57653760 (accessed 1 June 2015).
104. NCT00345137. Phase 1 study of systemic effects of Ng-monomethyl-L-arginine on renal hemodynamics in patients with polycystic kidney disease and chronic glomerulonephritis. www.clinicaltrials.gov/ct2/show/NCT00345137 (accessed 1 June 2015).
105. NCT01932450. A randomized, open-label study investigating the effect of bilateral renal artery sympathetic denervation by catheter-based radiofrequency ablation on blood pressure and disease progression in autosomal dominant polycystic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01932450 2013. [CENTRAL: CN-00874871]
106. Chang MY, Ong AC. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clinical Practice 2012;120(1):c25-34. [MEDLINE: 22205396]
107. Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Current Hypertension Reviews 2013;9(1):2-11. [MEDLINE: 23971638]
108. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2011. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2011. www.era-edta-reg.org/files/annualreports/pdf/AnnRep2011.pdf (accessed 1 June 2015).
109. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Medicine 2003;9(10):1323-6. [MEDLINE: 14502283]
110. Gile RD, Cowley BD Jr, Gattone VH 2nd, O'Donnell MP, Swan SK, Grantham JJ. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. American Journal of Kidney Diseases 1995;26(3):501-7. [MEDLINE: 7645559]
111. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, et al. Volume progression in polycystic kidney disease. New England Journal of Medicine 2006;354(20):2122-30. [MEDLINE: 16707749]
112. Grantham JJ, Cook LT, Torres VE, Bost JE, Chapman AB, Harris PC, et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney International 2008;73(1):108-16. [MEDLINE: 17960141]
113. Grantham JJ, Bennett WM, Perrone RD. mTOR inhibitors and autosomal dominant polycystic kidney disease. New England Journal of Medicine 2011;364(3):286-7. [MEDLINE: 21247328]
114. Hanaoka K, Guggino W. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. Journal of the American Society of Nephrology 2000;11(7):1179-87. [MEDLINE: 10864573]
115. Harris PC, Torres VE. Polycystic kidney disease. Annual Review of Medicine 2009;60:321-37. [MEDLINE: 18947299]
116. Helal I, Reed B, Schrier RW. Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. American Journal of Nephrology 2012;36(2):162-7. [MEDLINE: 22846584]
117. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
118. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
119. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3', 5'-cyclic monophosphate. Gastroenterology 2007;132(3):1104-16. [MEDLINE: 17383431]
120. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. Journal of the American Society of Nephrology 2006;17(8):2220-7. [MEDLINE: 16807403]
121. Ogborn MR, Nitschmann E, Weiler HA, Bankovic-Calic N. Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney International 2000;57(1):159-66. [MEDLINE: 10620197]
122. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology 2008;19(3):631-8. [MEDLINE: 18199797]
123. Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, et al. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. Journal of the American Society of Nephrology 2006;17(3):854-62. [MEDLINE: 16452494]
124. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology 2009;20(9):1888-93. [MEDLINE: 19696226]
125. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369(9569):1287-301. [MEDLINE: 17434405]
126. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney International 2009;76(2):149-68. [MEDLINE: 19455193]
127. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney International 2012;81(6):577-85. [MEDLINE: 22205355]
128. Table A.1.7 Incident counts of reported ESRD: all patients by age, gender, race, ethnicity, & primary diagnosis. IN: US Renal Data Services. Table A.1, Incident counts of reported ESRD: all patients. www.usrds.org/2008/ref/A_incidence:08.pdf (accessed 1 June 2015).
129. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrology Dialysis Transplantation 2006;21(3):598-604. [MEDLINE: 16221708]
130. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wüthrich RP, Serra AL. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney & Blood Pressure Research 2007;30(4):253-9. [MEDLINE: 17596700]
131. Wüthrich RP, Serra AL, Kistler AD. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney & Blood Pressure Research 2009;32(5):380-7. [MEDLINE: 19887826]
132. Bolignano D, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010294]